Collect Product
Product Details
Synonym
ICOS, CD278, AILIM, Inducible T-cell costimulator
Source
Human ICOS, Fc Tag (ICS-H5258) is expressed from human 293 cells (HEK293). It contains AA Glu 21 - Phe 141 (Accession # Q9Y6W8-1).
Predicted N-terminus: Glu 21
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 40.2 kDa. The protein migrates as 45-60 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Kunden haben auch angesehen
Data Display
SDS-PAGE
Human ICOS, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
Bioactivity-ELISA
Immobilized Human B7-H2, His Tag (Cat. No. B72-H5221) at 1 μg/mL (100 μL/well) can bind Human ICOS, Fc Tag (Cat. No. ICS-H5258) with a linear range of 0.4-6 ng/mL (QC tested).
Protocol
User Reviews Publish Comment
Background Introduction
Frontier Progress
Drug Development Progress- English Name：
Inducible T-cell costimulator
- Category：
- Listed Drugs Count：
0 Details
- Clinical Drugs Count：
7 Details
- Highest R&D Stage：
Phase 2 Clinical
Contact Us
Drug Candidate Licensing
